{
    "paper_id": "9f0a136b7ee1f93b59fd7ffed86854456512f792",
    "metadata": {
        "title": "ARTICLE IN PRESS G Model ScienceDirect Lettre \u00e0 la r\u00e9daction Epid\u00e9mie au nouveau coronavirus (SARS-CoV-2) et pres- cription de la clozapine: quelles mesures? Pourquoi?",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "La clozapine est un antipsychotique atypique indiqu\u00e9 dans le traitement de la schizophr\u00e9nie pharmaco-r\u00e9sistante ou en cas d'intol\u00e9rance neurologique s\u00e9v\u00e8re aux autres antipsychotiques et dans le traitement des troubles psychotiques survenant au cours de l'\u00e9volution de la maladie de Parkinson [1] . La prescription de cette mol\u00e9cule est entour\u00e9e de nombreuses mesures de pr\u00e9caution en raison des nombreux effets secondaires qu'elle engendre, notamment h\u00e9matologiques.",
            "cite_spans": [
                {
                    "start": 293,
                    "end": 296,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "En France, la prescription de la clozapine concerne environ huit personnes sur 10 000 avec une augmentation marqu\u00e9e dans les tranches d'\u00e2ges les plus \u00e9lev\u00e9es [2] .",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 161,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Dans les derni\u00e8res ann\u00e9es, plusieurs travaux ont point\u00e9 l'incidence plus importante d'infections pulmonaires chez les patients sous clozapine par rapport \u00e0 la population g\u00e9n\u00e9rale mais aussi par rapport \u00e0 des patients souffrant de pathologies psychiatriques s\u00e9v\u00e8res trait\u00e9es par d'autres antipsychotiques [3, 4] . L'inhalation de l'exc\u00e8s de salive induit par la clozapine est responsable de pneumonies, dites d'aspiration [5] qui repr\u00e9sentent une part importante de ces infections pulmonaires. D'autres pneumonies communautaires, iatrog\u00e8nes ou non sp\u00e9cifiques, \u00e9galement plus fr\u00e9quentes chez les patients sous clozapine [3] , soul\u00e8vent la question d'une action immunosuppressive de cette mol\u00e9cule.",
            "cite_spans": [
                {
                    "start": 304,
                    "end": 307,
                    "text": "[3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 308,
                    "end": 310,
                    "text": "4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 421,
                    "end": 424,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 619,
                    "end": 622,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Cette action passe en partie par une r\u00e9duction des taux circulants des immunoglobulines (Ig) des trois classes [6] . L'hypogammaglobulin\u00e9mie observ\u00e9e concerne \u00e9galement les Ig G sp\u00e9cifiques anti-haemophilus influenza et pneumocoques, pathog\u00e8nes communs du tractus respiratoire. L'ampleur de l'action immunosuppressive de la clozapine est comparable \u00e0 celle de l'association rituximab-methotrexate [7] . Elle est d'autant plus marqu\u00e9e que la dur\u00e9e de traitement par la clozapine est longue et ne semble pas \u00eatre dose d\u00e9pendante [6, 7] . Il est toutefois important de souligner les nombreux rapports de cas, associant dose \u00e9lev\u00e9e de clozapine et infection s\u00e9v\u00e8re [8] . La survenue de ces infections se complique en retour d'une \u00e9l\u00e9vation des concentrations plasmatiques de la clozapine par inhibition des cytochromes 1A2 et 3A4 par les m\u00e9diateurs de l'inflammation (TNF\u2423, IL-6 et CRP) entra\u00eenant hypers\u00e9dation et confusion mentale [9] .",
            "cite_spans": [
                {
                    "start": 111,
                    "end": 114,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 397,
                    "end": 400,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 527,
                    "end": 530,
                    "text": "[6,",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 531,
                    "end": 533,
                    "text": "7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 661,
                    "end": 664,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 929,
                    "end": 932,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Dans le contexte pand\u00e9mique actuel au nouveau coronavirus (SARS-CoV-2), les donn\u00e9es de la litt\u00e9rature ne permettent pas de se prononcer sur une plus grande vuln\u00e9rabilit\u00e9 des patients trait\u00e9s par la clozapine \u00e0 l'infection. En revanche, les risques de surinfection pulmonaire par d'autres pathog\u00e8nes sont r\u00e9els.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Dans notre service hospitalier de psychiatrie de secteur, nous avons pris la d\u00e9cision de ne pas initier de traitements par clozapine en p\u00e9riode \u00e9pid\u00e9mique. En ambulatoire, le suivi de nos patients trait\u00e9s par clozapine est renforc\u00e9 par des rappels t\u00e9l\u00e9phoniques d'information, et de v\u00e9rification de l'observance des mesures pr\u00e9ventives (confinement, distanciation sociale, mesures d'hygi\u00e8ne).",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "En cas d'apparition de sympt\u00f4mes infectieux (fi\u00e8vre, myalgies, asth\u00e9nie) et de signes de souffrance respiratoire, il est recommand\u00e9 de r\u00e9aliser une surveillance de la concentration plasmatique de la clozapine [10] . \u00c0 d\u00e9faut, une diminution de la dose de clozapine de moiti\u00e9 est pr\u00e9conis\u00e9e [10, 11] . La dose ant\u00e9rieure peut \u00eatre reprise trois jours apr\u00e8s la r\u00e9solution des sympt\u00f4mes (ou la normalisation de la CRP), des paliers sont recommand\u00e9s avant d'atteindre la dose initiale si l'interruption a \u00e9t\u00e9 prolong\u00e9e [11] .",
            "cite_spans": [
                {
                    "start": 209,
                    "end": 213,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 290,
                    "end": 294,
                    "text": "[10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 295,
                    "end": 298,
                    "text": "11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 515,
                    "end": 519,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D\u00e9claration de liens d'int\u00e9r\u00eats"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Avis sur les M\u00e9dicaments",
            "authors": [],
            "year": 2017,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Prescriber and institutional barriers and facilitators of clozapine use: A systematic review",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Verdoux",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Quiles",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Bachmann",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Schizophr Res",
            "volume": "201",
            "issn": "",
            "pages": "10--19",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months",
            "authors": [
                {
                    "first": "Z",
                    "middle": [
                        "R"
                    ],
                    "last": "Stoecker",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "George",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "O&apos;brien",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Int Clin Psychopharmacol",
            "volume": "32",
            "issn": "3",
            "pages": "155--60",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Rohde",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Siskind",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "De Leon",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Acta Psychiatr Scand",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Clozapine-associated aspiration pneumonia: case series and review of the literature: reply",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Gurrera",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Perry",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Psychosomatics",
            "volume": "60",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Ponsford",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Steven",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Bramhall",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Pathol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Clozapine is associated with secondary antibody deficiency",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ponsford",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Castle",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tahir",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Br J Psychiatry",
            "volume": "2018",
            "issn": "",
            "pages": "1--7",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Elevated clozapine levels associated with infection: A systematic review",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "S"
                    ],
                    "last": "Warren",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Schizophr Res",
            "volume": "192",
            "issn": "",
            "pages": "50--56",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "De Leon",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J clin psychiat",
            "volume": "65",
            "issn": "8",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Notice on Strengthening the Treatment and Management of Patients with Severe Mental Disorders during the Outbreak of the New Coronary Pneumonia",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "M\u00e9dicaments utilis\u00e9s en psychiatrie-Conduites \u00e0 tenir en cas de patients suspects et/ou confirm\u00e9s COVID+",
            "authors": [
                {
                    "first": "Pui-Ch. Charles",
                    "middle": [],
                    "last": "Perrens",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "A. Ben Dhia S. Hamzaoui F. Mouaffak * P\u00f4le 93G04 de Psychiatrie d'Adultes; EPS Ville Evrard. 5 rue du Dr Delafontaine 93200, Saint Denis, France",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}